MK-677 (Ibutamoren) Complete Drug-Drug Interaction Profile

The direct answer

MK-677 does not have a single dominant pharmacokinetic drug interaction the way many prescription drugs do. Its main interaction risk is pharmacodynamic: because it keeps GH and IGF-1 elevated for roughly 24 hours a day, it works against insulin and oral hypoglycemic agents, can lower total and free T4 in patients on thyroid therapy, and directly opposes the IGF-1-suppressing mechanism of tamoxifen and aromatase inhibitors used in hormone-receptor-positive breast cancer. Because MK-677 has never gone through FDA review, none of this is established by a label; it rests on receptor pharmacology and a small number of older clinical trials in healthy or GH-deficient adults, and some of the specific numbers circulating online are not verifiable against a primary source and should not be treated as precise.

What MK-677 is, and what is not established about it

MK-677 binds GHSR-1a, the same receptor activated by endogenous ghrelin, in the hypothalamus and pituitary. Receptor activation increases GH pulse amplitude, reduces somatostatin's inhibitory tone, and stimulates hepatic IGF-1 synthesis. Unlike injected GH, MK-677 is reported to preserve a pulsatile pattern of release rather than producing a flat elevation, though the degree to which this differs meaningfully from injected GH in terms of downstream interactions has not been well characterized.

What is not established: the compound's precise CYP450 metabolism, the magnitude of any CYP3A4-mediated interaction, and a validated dose-adjustment scheme for any interacting drug. Claims that specific inhibitors or inducers raise or lower MK-677 exposure by a stated percentage are plausible extrapolations from general CYP3A4 pharmacology, not confirmed MK-677-specific pharmacokinetic data. Treat any precise interaction percentage attached to MK-677 as an estimate requiring verification, not a package-insert-grade figure.

Insulin and oral hypoglycemic agents

This is the interaction category with the largest affected population and the most consistent underlying mechanism.

GH raises free fatty acid availability through lipolysis, and elevated free fatty acids reduce skeletal-muscle glucose uptake, producing a transient, dose-dependent insulin-resistant state. This is a well-described effect of GH excess generally (seen in acromegaly and in GH-replacement studies), and MK-677 trials in older adults have reported small increases in fasting glucose during use. The exact magnitude reported for MK-677 specifically varies across sources and should be confirmed against the original trial reports rather than assumed.

• Insulin (any regimen). Patients on insulin may need reassessment of their dose within the first weeks of MK-677 use, guided by home glucose monitoring rather than a fixed percentage adjustment.
• Metformin. No shared metabolic pathway exists; metformin is renally cleared and does not depend on CYP3A4. Its insulin-sensitizing action may partly offset MK-677's glucose-raising effect, but this is a pharmacodynamic counterbalance, not a pharmacokinetic interaction.
• Sulfonylureas (glipizide, glimepiride). MK-677's glucose-raising effect can produce unpredictable glycemic swings on a fixed sulfonylurea dose, and abrupt discontinuation of MK-677 in a patient whose sulfonylurea dose was raised to compensate could precipitate hypoglycemia.
• SGLT-2 inhibitors and GLP-1 receptor agonists (semaglutide, liraglutide). No pharmacokinetic interaction is expected because these drug classes do not depend on CYP3A4 or insulin signaling the same way. They may blunt the postprandial component of MK-677-associated hyperglycemia, but fasting glucose still needs monitoring.

Anyone with diabetes or prediabetes should treat MK-677 as a variable that can move glucose control in either direction and should not start or stop it without discussing glucose-monitoring frequency with the clinician managing their diabetes medications.

Glucocorticoids

Glucocorticoids and MK-677 interact through two separate mechanisms, which is why this combination carries elevated risk in both directions:

1. Chronic glucocorticoid use suppresses pituitary GH secretion and reduces the IGF-1 response to GH-axis stimulation. This is a well-established effect of glucocorticoid excess on the GH axis generally; the specific degree of blunting for MK-677 has not been confirmed in a dedicated study, so any stated percentage reduction in IGF-1 response should be treated as approximate.
2. Both glucocorticoids and MK-677 independently promote sodium and water retention and can raise glucose, so the combination plausibly compounds both blood pressure and glycemic risk rather than one drug offsetting the other.

Patients on moderate-to-high-dose glucocorticoids should not expect MK-677 to produce its usual IGF-1 rise, and should have blood pressure and glucose checked more frequently than a patient on MK-677 alone.

Thyroid hormones

Growth hormone axis activity is known to influence peripheral thyroid hormone handling; increased type 1 deiodinase activity under GH stimulation is one proposed mechanism by which total and free T4 can fall modestly without a corresponding TSH change. This pattern has been reported in older GH-secretagogue and GH-replacement literature, though the specific magnitude in MK-677 users has not been independently confirmed here and needs verification against the primary trial reports before being treated as a fixed number.

• Levothyroxine users. A relative decline in circulating T4 after starting MK-677 could re-emerge as subtle hypothyroid symptoms even with an unchanged TSH. A thyroid panel (TSH, free T4, and ideally free T3) some weeks after starting MK-677 is a reasonable check.
• Antithyroid drug users (methimazole, propylthiouracil). The same T4-lowering tendency could push an already-suppressed patient into over-treatment. Dose changes should be guided by repeat labs, not symptoms alone.

CYP3A4-related exposure and P-glycoprotein interactions

MK-677 is generally described as hepatically metabolized with CYP3A4 involvement, but the compound's metabolic pathway has not been characterized with the rigor of an approved drug, and there is no validated dose-adjustment table for CYP3A4 inhibitors or inducers.

• Strong CYP3A4 inhibitors (examples: ketoconazole, clarithromycin, ritonavir, grapefruit juice) could plausibly raise MK-677 exposure and intensify its effects on fluid retention, IGF-1, and glucose. No specific percentage increase in exposure for MK-677 is confirmed; general CYP3A4 pharmacology supports the direction of the effect, not a precise number.
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) could lower MK-677 exposure enough to blunt or eliminate its intended GH/IGF-1 effect, meaning a patient on chronic enzyme-inducing therapy may simply get no benefit at a standard dose rather than experiencing a dangerous interaction.
• Cyclosporine inhibits both CYP3A4 and P-glycoprotein and is used in transplant immunosuppression, a setting where unpredictable increases in MK-677 exposure are least acceptable. This combination should not be attempted without specialist transplant and endocrine input.

Fluid retention and cardiovascular medications

GH and IGF-1 promote renal sodium reabsorption, and dose-dependent fluid retention is one of the more consistently reported effects of GH secretagogues, including in early MK-677 trials in older adults.

• Loop diuretics and thiazides. Fluid retention from MK-677 can blunt the intended diuretic effect in patients being treated for heart failure or hypertension. Daily weight tracking is a reasonable way to catch this early; a noticeable weight gain over a short period should prompt reassessment rather than being attributed to diet alone.
• ACE inhibitors and ARBs. No pharmacokinetic interaction is expected; the concern is purely that GH-driven fluid retention can partially offset the blood-pressure-lowering effect of these drugs.
• Beta-blockers. Non-selective beta-blockade (propranolol and similar agents) is known to blunt hypothalamic GH secretion independently of MK-677's own mechanism, so patients on these drugs may see a smaller-than-expected IGF-1 response to MK-677 rather than a toxic interaction.

Anabolic and hormonal therapies used alongside MK-677

MK-677 is frequently combined off-label with testosterone replacement therapy, SARMs, or aromatase inhibitors. These combinations are common enough in off-label use that they deserve explicit treatment even though controlled interaction data are thin.

• Testosterone / TRT. Testosterone independently stimulates GH-axis activity, so combining TRT with MK-677 can push IGF-1 higher than either drug alone. Clinical guidance for testosterone therapy generally supports monitoring IGF-1 in men on TRT; adding MK-677 without a baseline and follow-up IGF-1 makes it impossible to tell which drug is driving an abnormal result.
• Aromatase inhibitors (anastrozole, letrozole). No shared CYP pathway of clinical concern is established. The theoretical pharmacodynamic issue is that estrogen partly restrains hepatic IGF-1 production, so suppressing estrogen could unmask a larger IGF-1 rise from MK-677. This is a plausible mechanism, not a confirmed clinical finding.
• Exogenous GH (somatropin). Combining MK-677 with injected GH risks additive, potentially supraphysiological IGF-1 elevation. Sustained IGF-1 well above the age-adjusted reference range is the kind of finding that, in other GH-axis conditions, is treated as needing dose reduction or discontinuation. This combination should only be attempted under endocrinologist supervision with regular IGF-1 monitoring.

Cancer risk and IGF-1-suppressing cancer therapies

This is the category with the most serious long-term stakes and the clearest pharmacodynamic conflict.

IGF-1 is a mitogenic signaling molecule, and higher circulating IGF-1 has been associated with increased risk of certain cancers in observational research, most consistently discussed for colorectal, breast, and prostate cancer. MK-677 is designed specifically to raise IGF-1. Tamoxifen and aromatase inhibitors, used as adjuvant therapy in hormone-receptor-positive breast cancer, work partly by reducing IGF-1 signaling. Adding MK-677 pharmacodynamically opposes that mechanism. There is no pharmacokinetic interaction here in the sense of altered drug levels; the conflict is that one drug is trying to raise a signal the other is trying to suppress.

People with a personal history of hormone-sensitive cancer, or a strong first-degree family history of colorectal, breast, or prostate cancer, should not start MK-677 without discussing this specific IGF-1 conflict with their oncology team. This is a case where the honest answer is narrower than a blanket reassurance: the concern is mechanistic and taken seriously by oncology practice patterns, even though a randomized trial directly testing MK-677 against cancer outcomes does not exist.

CNS-active and psychiatric medications

GHSR-1a is expressed outside the pituitary, including in the hippocampus and dopaminergic pathways, which is the basis for some of the CNS-related interaction concerns raised about MK-677.

• Antipsychotics (D2 antagonists) raise prolactin and can blunt GH secretion through hypothalamic dopaminergic pathways, potentially partially counteracting MK-677's intended effect. No pharmacokinetic interaction is described.
• Benzodiazepines and sleep-affecting drugs. Sleep architecture influences natural GH secretion, but there is no published trial directly characterizing how benzodiazepines change MK-677's effect. This should be described as uncertain rather than quantified.
• SSRIs/SNRIs. No firm pharmacokinetic interaction via CYP2D6 or CYP3A4 has been established at typical clinical doses. Higher-dose sertraline is a moderate CYP3A4 inhibitor and could modestly raise MK-677 exposure, though this has not been directly studied in MK-677 users.

Special populations

Type 2 diabetes. This is the population with the clearest, most mechanistically grounded interaction risk, because GH-induced insulin resistance layers on top of existing beta-cell dysfunction. Diabetes management guidelines generally call for closer glucose monitoring whenever a GH- or IGF-1-raising agent is introduced; anyone with diabetes considering MK-677 should treat this as a conversation with the clinician managing their diabetes care, not a self-directed decision.

Older adults. Age-related changes in glucose handling, fluid balance, and polypharmacy make interaction effects harder to predict, and MK-677 has not been studied broadly enough in this population to characterize interaction risk with confidence.

Renal impairment. The kidney is a meaningful clearance site for IGF-1, so reduced kidney function could plausibly amplify IGF-1 exposure and downstream interaction risk. No peer-reviewed renal dosing guidance for MK-677 exists, so any specific dose-reduction recommendation should be treated as an unverified estimate rather than an established rule.

Pediatric and adolescent use. MK-677 has not been studied in children or adolescents for any approved purpose, and stimulating an already-active GH axis during growth and puberty carries unknown risk to growth-plate biology and endocrine maturation. Pediatric endocrinology practice generally treats off-label GH-axis stimulation outside a registered trial as inappropriate.

Evidence boundary: what is established, what is plausible, what is not established

Established: MK-677 activates GHSR-1a and raises GH pulse amplitude and IGF-1; it has no FDA-approved indication and no official label; GH-axis stimulation generally raises fasting glucose and promotes fluid retention through well-described endocrine mechanisms seen in other GH-related conditions.

Plausible but not confirmed for MK-677 specifically: the precise percentage changes in glucose, IGF-1, diuretic efficacy, thyroid hormone levels, or CYP3A4-mediated exposure that appear in secondary summaries of MK-677. These numbers are drawn from general GH pharmacology or from small, older trials whose exact findings have not been verified against a primary source in this review and should not be repeated as fixed figures.

Not established: a validated MK-677 drug-interaction table of the kind found in an FDA label; safe combination protocols with exogenous GH, TRT, or CYP3A4-active drugs; long-term cancer outcome data in MK-677 users; and any pediatric safety or interaction data.

Readers should also not confuse MK-677 with macimorelin (Macrilen), a related but distinct, FDA-approved ghrelin-receptor agonist used only as a single-dose diagnostic test, or with recombinant human GH (somatropin), which has extensive labeled interaction and monitoring data that does not automatically transfer to MK-677.

MK-677 interaction decision framework

Because there is no label to consult, the practical question for a reader is not "does drug X interact with MK-677" in the abstract, but "what should change about my next dose or my next lab check." The table below sorts the interaction categories above into four action tiers.

Exception that changes the tier: any drug that is a strong CYP3A4 inhibitor (examples above) can push a "monitoring only" situation into "check with a clinician before combining," because it raises MK-677 exposure and intensifies every downstream effect at once, including glucose, fluid retention, and IGF-1.

When to seek urgent care rather than wait for a scheduled recheck: new or worsening shortness of breath, significant unexplained swelling, a blood glucose reading far outside a patient's usual range, or new visual changes or severe headache (which can signal significantly elevated IGF-1 activity) warrant same-day medical attention rather than waiting for the next monitoring interval.

Contraindicated or high-caution combinations, summarized

1. MK-677 with active treatment for hormone-receptor-positive breast cancer (tamoxifen, aromatase inhibitors), direct pharmacodynamic conflict.
2. MK-677 with exogenous GH without regular IGF-1 monitoring, additive IGF-1 risk.
3. MK-677 with cyclosporine, combined CYP3A4 and P-glycoprotein inhibition.
4. MK-677 in a patient with active acromegaly or IGF-1 already above the age-adjusted reference range.
5. MK-677 with a strong CYP3A4 inducer, if the goal is a therapeutic GH/IGF-1 effect, the combination is more likely to render MK-677 ineffective than dangerous, but it is still worth avoiding as a mismatch of intent and outcome.

A note on sources. MK-677 has no FDA-approved label, so there is no official interaction table to cite. Several precise figures that circulate in secondary summaries of MK-677 (specific percentage changes in glucose, IGF-1, or drug exposure) could not be verified against a primary source in this review and have been described qualitatively instead. Readers who need exact numbers for a clinical decision should ask the reviewing clinician to pull the original trial reports rather than relying on secondary summaries, including this one.